Synact Pharma intensifies partnership discussions

Fresh off receiving positive results from a phase IIa study with arthritis candidate AP1189, biotech firm Synact Pharma prepares to look into partnership options.

Photo: Synact Pharma / PR

Synact Pharma is going in with good cards in a hunt for potential partners. Last week, the biotech firm could reveal promising results from a smaller phase IIa study with its drug candidate, AP1189, against arthritis.

This makes it the opportune moment to look for potential partners, say the firm's CEO, Jeppe Øvlesen, and chief medical officer, Anders Dyhr Toft.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs